PATENT CLAIM ANALYSIS

Application Number: 16039245
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "454000"]

Abstract:
A medicinal agent for the prevention and/or treatment of diseases caused by EP 4  receptor activation. A compound having antagonistic activity against the EP 4  receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP 4  receptor for the prevention and/or treatment of diseases caused by EP 4  receptor activation.

Claim (Index 1):
A pharmaceutical composition comprising a compound that is 4-[4-cyano-2-({[(2\u2032R,4S)-6-(isopropylcarbamoyl)-2,3-dihyd rospiro[chromene-4,1\u2032-cyclopropan]-2\u2032-yl]carbonyl}amino)phenyl]butanoic acid, a salt thereof, or a solvate thereof as an active ingredient.

Metadata:
- Claim Count in Document: 10.0
- Percentile: 95.0
- Lexical Diversity: 1.98
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15542216', '10583469', '11662639', '13682784', '13016849']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7772846933251186
- 35 USC 102 Novelty (BERT): 0.5901753844011446
- Combined Prediction Score: 0.7585737624327212
- Mean Citation Score: 312.68893799999995
- Max Citation Score: 493.8849
- Similarity Product: 471.9397601184726

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test